MedPath

VEVYE

These highlights do not include all the information needed to use VEVYE safely and effectively. See full prescribing information for VEVYE. VEVYE (cyclosporine ophthalmic solution) 0.1%, for topical ophthalmic use Initial U.S. Approval: 1983

Approved
Approval ID

0a60fccf-7e1b-44fe-e063-6394a90aadd5

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 21, 2023

Manufacturers
FDA

Harrow Eye, LLC

DUNS: 118526951

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

cyclosporine ophthalmic solution

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code82667-900
Application NumberNDA217469
Product Classification
M
Marketing Category
C73594
G
Generic Name
cyclosporine ophthalmic solution
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateNovember 21, 2023
FDA Product Classification

INGREDIENTS (3)

ALCOHOLInactive
Quantity: 12.9 mg in 1 mL
Code: 3K9958V90M
Classification: IACT
CYCLOSPORINEActive
Quantity: 1 mg in 1 mL
Code: 83HN0GTJ6D
Classification: ACTIB
1,1,1,2,2,3,3,4,4-NONAFLUORONONANEInactive
Quantity: 1276.5 mg in 1 mL
Code: M4M23ZL2AD
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.